Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]

por Orsatti, Leticia, Fortea, Josep, Quaresma, Manuel
Publicado 2019

Fibrosing interstitial lung diseases: knowns and unknowns

por Cottin, Vincent, Wollin, Lutz, Fischer, Aryeh, Quaresma, Manuel, Stowasser, Susanne, Harari, Sergio
Publicado 2019

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

por Valenzuela, Claudia, Torrisi, Sebastiano Emanuele, Kahn, Nicolas, Quaresma, Manuel, Stowasser, Susanne, Kreuter, Michael
Publicado 2020

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (...

por Behr, Jürgen, Kolb, Martin, Song, Jin Woo, Luppi, Fabrizio, Schinzel, Birgit, Stowasser, Susanne, Quaresma, Manuel
Publicado 2019

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

por Richeldi, Luca, Kolb, Martin, Jouneau, Stéphane, Wuyts, Wim A., Schinzel, Birgit, Stowasser, Susanne, Quaresma, Manuel, Raghu, Ganesh
Publicado 2020

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON

por Song, Jin Woo, Ogura, Takashi, Inoue, Yoshikazu, Xu, Zuojun, Quaresma, Manuel, Stowasser, Susanne, Stansen, Wibke, Crestani, Bruno
Publicado 2019

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

por Lancaster, Lisa, Crestani, Bruno, Hernandez, Paul, Inoue, Yoshikazu, Wachtlin, Daniel, Loaiza, Lazaro, Quaresma, Manuel, Stowasser, Susanne, Richeldi, Luca
Publicado 2019

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

por Glaspole, Ian, Bonella, Francesco, Bargagli, Elena, Glassberg, Marilyn K., Caro, Fabian, Stansen, Wibke, Quaresma, Manuel, Orsatti, Leticia, Bendstrup, Elisabeth
Publicado 2021

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

por Corte, Tamera, Bonella, Francesco, Crestani, Bruno, Demedts, Maurits G., Richeldi, Luca, Coeck, Carl, Pelling, Katy, Quaresma, Manuel, Lasky, Joseph A.
Publicado 2015

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares

por Choon, Siew Eng, Lebwohl, Mark G, Turki, Hamida, Zheng, Min, Burden, A. David, Li, Ling, Quaresma, Manuel, Thoma, Christian, Bachelez, Hervé
Publicado 2023

Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA

por Olson, Amy L., Maher, Toby M., Acciai, Valentina, Mounir, Baher, Quaresma, Manuel, Zouad-Lejour, Leila, Wells, Christopher D., De Loureiro, Lou
Publicado 2020

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

por Jouneau, Stéphane, Crestani, Bruno, Thibault, Ronan, Lederlin, Mathieu, Vernhet, Laurent, Valenzuela, Claudia, Wijsenbeek, Marlies, Kreuter, Michael, Stansen, Wibke, Quaresma, Manuel, Cottin, Vincent
Publicado 2020

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study...

por Morita, Akimichi, Tsai, Tsen‐Fang, Yee, Evelyn Yap Wen, Okubo, Yukari, Imafuku, Shinichi, Zheng, Min, Li, Ling, Quaresma, Manuel, Thoma, Christian, Choon, Siew Eng
Publicado 2022

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

por Richeldi, Luca, Kreuter, Michael, Selman, Moisés, Crestani, Bruno, Kirsten, Anne-Marie, Wuyts, Wim A, Xu, Zuojun, Bernois, Katell, Stowasser, Susanne, Quaresma, Manuel, Costabel, Ulrich
Publicado 2018

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial

por Noth, Imre, Cottin, Vincent, Chaudhuri, Nazia, Corte, Tamera J., Johannson, Kerri A., Wijsenbeek, Marlies, Jouneau, Stephane, Michael, Andreas, Quaresma, Manuel, Rohr, Klaus B., Russell, Anne-Marie, Stowasser, Susanne, Maher, Toby M.
Publicado 2021

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil

por Pereira, Carlos Alberto de Castro, Baddini-Martinez, José Antonio, Baldi, Bruno Guedes, Jezler, Sérgio Fernandes de Oliveira, Rubin, Adalberto Sperb, Alves, Rogerio Lopes Rufino, Zonzin, Gilmar Alves, Quaresma, Manuel, Trampisch, Matthias, Rabahi, Marcelo Fouad
Publicado 2019

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score

por Kuwana, Masataka, Allanore, Yannick, Denton, Christopher P., Distler, Jörg H. W., Steen, Virginia, Khanna, Dinesh, Matucci‐Cerinic, Marco, Mayes, Maureen D., Volkmann, Elizabeth R., Miede, Corinna, Gahlemann, Martina, Quaresma, Manuel, Alves, Margarida, Distler, Oliver
Publicado 2022

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

por Matteson, Eric L., Kelly, Clive, Distler, Jörg H. W., Hoffmann‐Vold, Anna‐Maria, Seibold, James R., Mittoo, Shikha, Dellaripa, Paul F., Aringer, Martin, Pope, Janet, Distler, Oliver, James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne, Quaresma, Manuel, Flaherty, Kevin R.
Publicado 2022